Message from the CEO

At Alkermes, our goal is to build a biotechnology company focused on bringing innovative medicines to patients, helping them lead better lives. Our approach leverages scientific expertise and technology platforms to develop new medicines that offer patients far more than enhanced compliance or convenience. We are committed to developing medications designed to improve clinical outcomes through better efficacy and improved safety.

We partner with some of the world's best pharmaceutical and biotechnology companies to develop breakthrough products in major diseases such as schizophrenia and diabetes. In addition, we are developing our own products in therapeutic areas with great unmet need, such as addiction and respiratory disease. And as we continue to build a successful commercial enterprise, we will increasingly invest in a portfolio of independently developed candidates.

We have established ourselves as a strong player with proven, proprietary technologies, an exceptional R&D team and world-class commercial scale manufacturing. Now we are entering a phase of growth that few biotechnology companies can match.

With two commercial products and an exciting late-stage pipeline, we are moving ahead with confidence in our science, confidence in our approach to innovation and, above all, confidence in our people. We are passionate about our goals and highly optimistic about the future.

We welcome your interest in our company.

Sincerely,

Richard F. Pops, Chairman, President and Chief Executive Officer